

Microsatellite Instability and Cancers

Guest Editors:

Dr. David Tougeron

Gastroenterology department,
Poitiers University Hospital,
86021 Poitiers, France

Dr. Violaine Randrian

Gastroenterology department,
Poitiers University Hospital,
86021 Poitiers, France


Deadline for manuscript
submissions:

closed (30 April 2021)

Message from the Guest Editors

Microsatellite instability (MSI) was first described in inherited malignancies associated with Lynch syndrome and later in sporadic colon, gastric, and endometrial cancers. MSI tumors develop through a distinctive molecular pathway characterized by genetic instability in numerous microsatellite DNA repeat sequences throughout the genome and are associated with inactivating alterations in mismatch repair genes (MMR). MMR / MSI testing is important for identifying Lynch syndrome but also for decision making of adjuvant chemotherapy in colorectal cancer (CRC) and today has become indispensable in testing many tumors due to the high efficacy of immune checkpoints inhibitors in dMMR / MSI tumors. Recent advances have greatly contributed to increasing our knowledge of dMMR/MSI cancers, laying the foundation for personalized medicine of dMMR/MSI tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)